# SIRT2-IN-11

Cat. No.: HY-148408 CAS No.: 1005095-06-6 Molecular Formula:  $C_{21}H_{22}N_{2}O$ Molecular Weight: 318.41

Pathway: Cell Cycle/DNA Damage; Epigenetics

Sirtuin

4°C, protect from light Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

Target:

DMSO: 250 mg/mL (785.15 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.1406 mL	15.7030 mL	31.4060 mL
	5 mM	0.6281 mL	3.1406 mL	6.2812 mL
	10 mM	0.3141 mL	1.5703 mL	3.1406 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC $_{50}$  value of 18.5  $\mu$ M. SIRT2-IN-11 p53-dependently induces

apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for

the research of p53-related cancers<sup>[1]</sup>.

IC<sub>50</sub> & Target SIRT2 SIRT1

> 118.4 μM (IC<sub>50</sub>) 18.5 μM (IC<sub>50</sub>)

In Vitro SIRT2-IN-11 (0-1000 μM) shows inhibitory effect of SIRT2-dependent deacetylation of MAL with an IC<sub>50</sub> value of 18.5 μM<sup>[1]</sup>.

SIRT2-IN-11 (0-1000  $\mu\text{M})$  weakly inhibits SIRT1 with an IC  $_{50}$  value of 118.4  $\mu\text{M}^{[1]}.$ 

SIRT2-IN-11 (0-20 μM; 8 h) induces cell apoptosis of lung cancer cells<sup>[1]</sup>.

SIRT2-IN-11 (20 μM; 6 h) increases p53 acetylation and expression levels of Cp53 target genes CDKN1A, PUMA and NOXA<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

 $\mathsf{RT}\text{-}\mathsf{PCR}^{[1]}$ 

NSCLC cell lines Cell Line:

Concentration:	20 μΜ	
Incubation Time:	6 hours	
Result:	Increased the expression of CDKN1A, PUMA and NOXA.	
Apoptosis Analysis <sup>[1]</sup>		
Cell Line:	A549 cell line	
Concentration:	0, 0.5, 1, 5, 10 and 20 μM	
Incubation Time:	24 hours	
Result:	Mildly increased apoptosis of A549 cells, but when combined treatment with etoposide caused a marked increase in apoptosis.	

## **REFERENCES**

[1]. Hoffmann G, et al. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 2014 Feb 21;289(8):5208-16.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA